Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Cancer Prevention02:59

Cancer Prevention

6.5K
Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
6.5K
Clinical Trials01:16

Clinical Trials

8.5K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
8.5K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K
Relative Risk01:12

Relative Risk

2.5K
Relative risk (RR) is a statistical measure commonly used in epidemiology to compare the likelihood of a particular event occurring between two groups. This metric is important for evaluating the relationship between exposure to a specific risk factor and the probability of a particular outcome. It plays a crucial role in medical research, public health studies, and risk assessment. Relative risk quantifies how much more (or less) likely an event is to occur in an exposed group compared to an...
2.5K
Cancer Survival Analysis01:21

Cancer Survival Analysis

870
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
870
Hazard Ratio01:12

Hazard Ratio

786
The hazard ratio (HR) is a widely used measure in clinical trials to compare the risk of events, such as death or disease recurrence, between two groups over time. It reflects the ratio of hazard rates—the instantaneous risk of the event occurring—between a treatment group and a control group. This measure provides valuable insights into the relative effectiveness of a treatment by assessing how the risk of an event differs between the two groups.
For example, in a clinical trial...
786

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Cluster randomized controlled trial of decision support for breast cancer chemoprevention, MiCHOICE.

Journal of the National Cancer Institute·2026
Same author

Impact of Population-Based Pathogenic Variant Testing on Risk-Based Breast Screening Recommendations: A Secondary Analysis of the WISDOM Study.

JAMA oncology·2026
Same author

WISDOM randomized trial comparing risk-based versus annual breast cancer screening: study cohort characteristics and design.

NPJ breast cancer·2026
Same author

Autostaining Immune Multiplex Immunohistochemistry Panels and Imaging Analysis.

Methods in molecular biology (Clifton, N.J.)·2026
Same author

Targeting Wnt/β-catenin and circadian regulator restores PRC2/EZH2-controlled chromatin bivalency and suppresses cell state diversity.

The Journal of clinical investigation·2026
Same author

Breast cancer risk level and prediction of tumor aggressiveness in the Athena Breast Health Network.

Breast cancer research and treatment·2026
Same journal

WHO Issues Guidelines for Treating Ebola and Marburg Viruses.

JAMA·2026
Same journal

FDA Approves Additional Naloxone Nasal Spray for Opioid Overdose.

JAMA·2026
Same journal

HIV May Hide in More Cells Than Previously Thought-Here's What That Could Mean for a Cure.

JAMA·2026
Same journal

US Dietary Supplement Use Increasing, Especially in Older Adults.

JAMA·2026
Same journal

Heat Stress From Climate Change Surges Globally.

JAMA·2026
Same journal

Strength Training Linked With Lower Cardiovascular Disease Risk in Women.

JAMA·2026
查看所有相关文章

相关实验视频

Updated: May 6, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.7K

基于风险的每年乳腺癌查:WISDOM随机临床试验

Laura J Esserman1, Allison S Fiscalini1, Arash Naeim2

  • 1University of California, San Francisco.

JAMA
|December 12, 2025
PubMed
概括
此摘要是机器生成的。

基于风险的乳腺癌查将女性按遗传风险和查强度分层. 虽然这种方法是安全的,但与每年进行的乳房检查相比,它并没有降低活检率.

更多相关视频

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.5K
Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial
03:07

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial

Published on: August 19, 2025

766

相关实验视频

Last Updated: May 6, 2026

Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

10.7K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.5K
Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial
03:07

Single-Port Robotic-assisted Transaxillary Breast-conserving Surgery: A Prospective, Single-arm, Non-randomized Phase IIa Clinical Trial

Published on: August 19, 2025

766

科学领域:

  • 癌症学
  • 遗传学
  • 预防医学

背景情况:

  • 个体乳腺癌风险评估可以优化查策略.
  • 目前的查方法可能无法有效地分配资源给高风险的个人.

研究的目的:

  • 评估基于风险的乳腺癌查是否可行,作为每年进行乳房检查的替代方案.
  • 确定风险分层是否可以改善查结果.

主要方法:

  • 一项实用的多中心随机临床试验将基于风险的查与年龄在40-74岁的女性的乳房检查进行了比较.
  • 风险评估包括基因测序,多基因风险评分和验证的风险模型.
  • 根据计算的5年风险和遗传因素,查建议有所不同.

主要成果:

  • 与年度查相比,基于风险的查在检测 ≥IIB 癌症方面没有劣势,但并没有降低活检率.
  • 在基于风险的组中进行的乳房影像较少,但活检率并没有显著下降.
  • 癌症发病率,活检,乳房影像和核磁共振成像率随着风险较高而增加.

结论:

  • 基于风险的乳腺癌查,包括基因检测,有效分层的风险和查强度.
  • 这种方法并没有降低活检率.
  • 可能需要进一步的研究来优化基于风险的查方案,以减少不必要的活检.